Skip to main content
European Commission logo
Enterprise Europe Network

Pharmaceutical companies, SMEs, academia, hospitals, partners from health sector sought for the co-development of breakthrough therapies in Type 1 Diabetes (T1D) or in Type 2 Diabetes (T2D) or european projects

Summary

Profile Type
  • Technology request
POD Reference
TRFR20251009013
Term of Validity
9 October 2025 - 9 October 2026
Company's Country
  • France
Type of partnership
  • Research and development cooperation agreement
Targeted Countries
  • All countries
Contact the EEN partner nearest to you for more information.
Find my local partner

General information

Short Summary
A french biotech start-up dedicated to the development of muscle secretome-based biotherapies to cure type 1 (T1D) & type 2 (T2D) diabetes is interested to develop breakthrough therapies. Main objective is to alleviate the burden of daily diabetes management and eliminate severe complications like renal failure, heart attack and so on. Partners specialized in T1D, stem-cells, immune modulating specialists, bioproduction, biomarker analysis, are sought under technological and/or R&D agreement.
Full Description
A french start-up, young spin-off from at the European Center of Diabetes (CeeD) which has more than 30 years of expertise in this field, is developing first-in-class biotherapies derived from the muscle secretome to treat diabetes and other metabolic diseases (NASH, obesity, etc.).

They are a preclinical stage biopharmaceutical company dedicated to developing of first-in-class biotherapies against diabetes and metabolic diseases, harvesting the breakthrough potential of the muscle secretome to regulate metabolism, a novel and unexplored approach.

Their research activites focus on achieving the first functional cure for T1D by enhancing beta cell replacement therapies (pancreatic islet or stem cell transplant). The innovation is a unique combination of pre- and post-transplant treatments based on their product, ensuring better islet survival at every step of the transplant, limiting graft rejection and enhancing its potency in the long term.

The team combines expertises in endocrinology, metabolic diseases, islet isolation process for grafts, pharmacology, molecular biology, biochemistry, primary cell cultures and cell lines (pancreatic cells, adipocytes, etc.).
Advantages and Innovations
Within the framework of co-development or EU project, the company is highly interested to contribute to the development of T1D functionnal cure to alleviate the burden of daily diabetes management and eliminate severe complications like renal failure or heart stroke, which causes patients to endure expensive and debilitating treatments and reduces their life expectancy
Technical Specification or Expertise Sought
The company is searching for ppartners from pharmaceutical companies, SME, academia, hospitals from medical and health sectors with specialization in:
- T1D,
- Stem-cells manufacturing,
- Immune modulating specialists,
- Bioproduction,
- Biomarker analysis.

The company is also interested by European projects.
Stage of Development
  • Concept stage
Sustainable Development Goals
  • Goal 3: Good Health and Well-being
IPR status
  • Secret know-how

Partner Sought

Expected Role of a Partner
- Type: pharmaceutical companies, SME, academia, hospitals, patient organisations, healthcare providers, policy makers
- Role: technological partners, R&D partners, project coordinator,

- Task(s) to be done:
* Contribution to the development and co-development of new of breakthrough therapies in Type 1 Diabetes (T1D) or in Type 2 Diabetes (T2D)
* Contribution to the work packages writing and implementation in case of European projects
Type and Size of Partner
  • SME <=10
Type of partnership
  • Research and development cooperation agreement

Dissemination

Technology keywords
  • 03007 - Sound Engineering/Technology
  • 06002001 - Biochemistry / Biophysics
  • 06001015 - Pharmaceutical Products / Drugs
  • 06001012 - Medical Research
  • 06002002 - Cellular and Molecular Biology
Market keywords
  • 05005003 - Endocrinology
Sector Groups Involved
  • Health
Targeted countries
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antarctica
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bonaire, Saint Eustatius and Saba
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cabo Verde
  • Cambodia
  • Cameroon
  • Canada
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Cook Islands
  • Costa Rica
  • Croatia
  • Cuba
  • Curacao
  • Cyprus
  • Czechia
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Eswatini
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and McDonald Islands
  • Honduras
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Ivory Coast
  • Jamaica
  • Japan
  • Jersey
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macao
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • North Korea
  • North Macedonia
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestinian Territory
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Republic of the Congo
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthelemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and the South Sandwich Islands
  • South Korea
  • South Sudan
  • Spain
  • Sri Lanka
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Sweden
  • Switzerland
  • Syria
  • Taiwan
  • Tajikistan
  • Tanzania
  • Thailand
  • Timor Leste
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • U.S. Virgin Islands
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Vatican
  • Venezuela
  • Vietnam
  • Wallis and Futuna
  • Western Sahara
  • Yemen
  • Zambia
  • Zimbabwe